Pharmaceutical

ESC 2024: CATHEDRAL-HF trial results have the potential to reduce polypharmacy

A large proportion of chronic heart failure (HF) patients are taking suboptimal doses of relevant medications.

Sep 2, 2024 - 04:00
ESC 2024: CATHEDRAL-HF trial results have the potential to reduce polypharmacy
A large proportion of chronic heart failure (HF) patients are taking suboptimal doses of relevant medications.
Read the original article

Tags:

Previous Article

Singapore scientists to use exosomes secreted by living cells to successfully ta...

Next Article

Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new ana...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

New medications for PCOS slowly edge toward development

New medications for PCOS slowly edge toward development

Mar 23, 2023

STAT+: Study on Amgen’s ‘bispecific’ immunotherapy could lead to approval in small cell lung cancer

STAT+: Study on Amgen’s ‘bispecific’ immunotherapy coul...

Oct 20, 2023

STAT+: Major pharma companies call on their suppliers to reduce carbon footprints

STAT+: Major pharma companies call on their suppliers t...

Jul 22, 2023